<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36939974</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>16</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1434-9949</ISSN><JournalIssue CitedMedium="Internet"><Volume>42</Volume><Issue>7</Issue><PubDate><Year>2023</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Clinical rheumatology</Title><ISOAbbreviation>Clin Rheumatol</ISOAbbreviation></Journal><ArticleTitle>Low estimated glomerular filtration rate is an independent risk factor for higher hydroxychloroquine concentration.</ArticleTitle><Pagination><StartPage>1943</StartPage><EndPage>1950</EndPage><MedlinePgn>1943-1950</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10067-023-06576-x</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The aim of this study was to analyze the relationship of the estimated glomerular filtration rate (eGFR) to hydroxychloroquine (HCQ) blood concentrations in systemic lupus erythematosus (SLE) patients.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Patients with SLE who had been taking HCQ for more than 12&#xa0;months were recruited. All subjects gave written informed consent. Various clinical characteristics and laboratory values were examined. The blood concentration of HCQ was measured by high-performance liquid chromatography, and the relationship of eGFR to HCQ blood concentration was mainly investigated.</AbstractText><AbstractText Label="RESULT" NlmCategory="RESULTS">In total, 115 patients with SLE receiving long-term HCQ therapy were included in the study. The median concentration of HCQ was 1096&#xa0;ng/ml (range 116-8240&#xa0;ng/ml). The eGFR was strongly associated with blood concentration of HCQ (P&#x2009;=&#x2009;0.011, P&#x2009;&lt;&#x2009;0.05), when adjusted for age, sex, body mass index (BMI), weight-adjusted dose, prednisone use and immunosuppressive drug use. No statistically significant association were found between age, duration, BMI, weight-adjusted HCQ dose, corticosteroid use, immunosuppressant use and blood concentrations of HCQ.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">We provided novel evidence that impaired renal function influenced the blood concentration of HCQ. Patients with low eGFR need to adjust the HCQ dosage according to the monitoring results of HCQ blood concentrations.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhong</LastName><ForeName>Xue</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Peking University People's Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Yue-Bo</ForeName><Initials>YB</Initials><AffiliationInfo><Affiliation>Department of Rheumatology &amp; Immunology, Peking University People's Hospital, No. 11 South Avenue, Xi Zhi Men, Xicheng District, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Qin</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Ophthalmology Optometry Centre, Peking University People's Hospital, Beijing, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Key Laboratory of Diagnosis and Therapy of Retinal and Choroid Diseases, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Si-Lu</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Peking University People's Hospital, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Jing</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-3904-8928</Identifier><AffiliationInfo><Affiliation>Department of Rheumatology &amp; Immunology, Peking University People's Hospital, No. 11 South Avenue, Xi Zhi Men, Xicheng District, Beijing, China. hejing1105@126.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Clin Rheumatol</MedlineTA><NlmUniqueID>8211469</NlmUniqueID><ISSNLinking>0770-3198</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018501">Antirheumatic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018501" MajorTopicYN="Y">Antirheumatic Agents</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005919" MajorTopicYN="N">Glomerular Filtration Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Blood concentration</Keyword><Keyword MajorTopicYN="N">Estimated glomerular filtration rate</Keyword><Keyword MajorTopicYN="N">Hydroxychloroquine</Keyword><Keyword MajorTopicYN="N">Systemic lupus erythematosus</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Research funding played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>7</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>3</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>16</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>20</Day><Hour>12</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36939974</ArticleId><ArticleId IdType="pmc">PMC10267264</ArticleId><ArticleId IdType="doi">10.1007/s10067-023-06576-x</ArticleId><ArticleId IdType="pii">10.1007/s10067-023-06576-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ruiz-Irastorza G, Mart&#xed;n-Iglesias D, Soto-Peleteiro A. Update on antimalarials and systemic lupus erythematosus. Curr Opin Rheumatol. 2020;32:572&#x2013;582. doi: 10.1097/BOR.0000000000000743.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BOR.0000000000000743</ArticleId><ArticleId IdType="pubmed">32890029</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi CM, Hamijoyo L, Kasitanon N, Chen DY, Tanaka Y (2021) The asia-pacific league of associations for rheumatology consensus statements on the management of systemic lupus erythematosus. The Lancet Rheumatol 3:e517&#x2013;e531. 10.1016/S2665-9913(21)00009-6</Citation></Reference><Reference><Citation>Costedoat-Chalumeau N, Galicier L, Auma&#xee;tre O, Franc&#xe8;s C, Le Guern V, Liot&#xe9; F, Smail A, Limal N, Perard L, Desmurs-Clavel H, du Boutin LT, Asli B, Kahn JE, Pourrat J, Sailler L, Ackermann F, Papo T, Sacr&#xe9; K, Fain O, Stirnemann J, Cacoub P, Jallouli M, Leroux G, Cohen-Bittan J, Tanguy ML, Hulot JS, Lechat P, Musset L, Amoura Z, Piette JC, Group PLUS Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study) Ann Rheum Dis. 2013;72:1786&#x2013;1792. doi: 10.1136/annrheumdis-2012-202322.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2012-202322</ArticleId><ArticleId IdType="pubmed">23144449</ArticleId></ArticleIdList></Reference><Reference><Citation>Costedoat-Chalumeau N, Amoura Z, Hulot JS, Aymard G, Leroux G, Marra D, Lechat P, Piette JC. Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus. Ann Rheum Dis. 2007;66:821&#x2013;824. doi: 10.1136/ard.2006.067835.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2006.067835</ArticleId><ArticleId IdType="pmc">PMC1954674</ArticleId><ArticleId IdType="pubmed">17324970</ArticleId></ArticleIdList></Reference><Reference><Citation>Costedoat-Chalumeau N, Le Guern V, Piette JC. Determining adherence to therapeutic regimens in patients with chronic illness: comment on the article by Waimann et AI. Arthritis Rheumatol. 2014;66:770. doi: 10.1002/art.38243.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.38243</ArticleId><ArticleId IdType="pubmed">24574241</ArticleId></ArticleIdList></Reference><Reference><Citation>Costedoat-Chalumeau N, Pouchot J, Guettrot-Imbert G, Le Guern V, Leroux G, Marra D, Morel N, Piette JC. Adherence to treatment in systemic lupus erythematosus patients. Best Pract Res Clin Rheumatol. 2013;27:329&#x2013;340. doi: 10.1016/j.berh.2013.07.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.berh.2013.07.001</ArticleId><ArticleId IdType="pubmed">24238690</ArticleId></ArticleIdList></Reference><Reference><Citation>Ting TV, Kudalkar D, Nelson S, Cortina S, Pendl J, Budhani S, Neville J, Taylor J, Huggins J, Drotar D, Brunner HI. Usefulness of cellular text messaging for improving adherence among adolescents and young adults with systemic lupus erythematosus. J Rheumatol. 2012;39:174&#x2013;179. doi: 10.3899/jrheum.110771.</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.110771</ArticleId><ArticleId IdType="pubmed">22089460</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M, Elkhalifa M, Li J, Magder LS, Goldman DW. Hydroxychloroquine Blood Levels Predict Hydroxychloroquine Retinopathy. Arthritis Rheumatol. 2020;72:448&#x2013;453. doi: 10.1002/art.41121.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.41121</ArticleId><ArticleId IdType="pmc">PMC7050401</ArticleId><ArticleId IdType="pubmed">31532077</ArticleId></ArticleIdList></Reference><Reference><Citation>Carmichael SJ, Day RO, Tett SE. A cross-sectional study of hydroxychloroquine concentrations and effects in people with systemic lupus erythematosus. Intern Med J. 2013;43:547&#x2013;553. doi: 10.1111/imj.12100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imj.12100</ArticleId><ArticleId IdType="pubmed">23425382</ArticleId></ArticleIdList></Reference><Reference><Citation>Costedoat-Chalumeau N, Amoura Z, Hulot JS, Hammoud HA, Aymard G, Cacoub P, Franc&#xe8;s C, Wechsler B, du Huong LT, Ghillani P, Musset L, Lechat P, Piette JC. Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum. 2006;54:3284&#x2013;3290. doi: 10.1002/art.22156.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.22156</ArticleId><ArticleId IdType="pubmed">17009263</ArticleId></ArticleIdList></Reference><Reference><Citation>Tett S, Day R, Cutler D. Hydroxychloroquine relative bioavailability: within subject reproducibility. Br J Clin Pharmacol. 1996;41:244&#x2013;246. doi: 10.1111/j.1365-2125.1996.tb00190.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2125.1996.tb00190.x</ArticleId><ArticleId IdType="pubmed">8866926</ArticleId></ArticleIdList></Reference><Reference><Citation>Jallouli M, Galicier L, Zahr N, Auma&#xee;tre O, Franc&#xe8;s C, Le Guern V, Liot&#xe9; F, Smail A, Limal N, Perard L, Desmurs-Clavel H, Le Thi Huong D, Asli B, Kahn JE, Pourrat J, Sailler L, Ackermann F, Papo T, Sacr&#xe9; K, Fain O, Stirnemann J, Cacoub P, Leroux G, Cohen-Bittan J, Sellam J, Mariette X, Blanchet B, Hulot JS, Amoura Z, Piette JC, Costedoat-Chalumeau N, Plaquenil Lupus Systemic Study Group Determinants of hydroxychloroquine blood concentration variations in systemic lupus erythematosus. Arthritis Rheumatol. 2015;67:2176&#x2013;84. doi: 10.1002/art.39194.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.39194</ArticleId><ArticleId IdType="pubmed">25989906</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeon Lee J, Lee J, Ki Kwok S, Hyeon JuJ, Su Park K, Park SH. Factors Related to Blood Hydroxychloroquine Concentration in Patients With Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken) 2017;69:536&#x2013;542. doi: 10.1002/acr.22962.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.22962</ArticleId><ArticleId IdType="pubmed">27390146</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JY, Luc S, Greenblatt DJ, Kalish R, McAlindon TE. Factors associated with blood hydroxychloroquine level in lupus patients: renal function could be important. Lupus. 2013;22(5):541&#x2013;542. doi: 10.1177/0961203313476361.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203313476361</ArticleId><ArticleId IdType="pubmed">23396569</ArticleId></ArticleIdList></Reference><Reference><Citation>Durcan L, Clarke WA, Magder LS, Petri M. Hydroxychloroquine Blood Levels in Systemic Lupus Erythematosus: Clarifying Dosing Controversies and Improving Adherence. J Rheumatol. 2015;42:2092&#x2013;2097. doi: 10.3899/jrheum.150379.</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.150379</ArticleId><ArticleId IdType="pmc">PMC4630115</ArticleId><ArticleId IdType="pubmed">26428205</ArticleId></ArticleIdList></Reference><Reference><Citation>Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J, CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604&#x2013;612. doi: 10.7326/0003-4819-150-9-200905050-00006.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-150-9-200905050-00006</ArticleId><ArticleId IdType="pmc">PMC2763564</ArticleId><ArticleId IdType="pubmed">19414839</ArticleId></ArticleIdList></Reference><Reference><Citation>National Kidney Foundation K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:S1&#x2013;266.</Citation><ArticleIdList><ArticleId IdType="pubmed">11904577</ArticleId></ArticleIdList></Reference><Reference><Citation>Melles RB, Marmor MF. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol. 2014;132:1453&#x2013;1460. doi: 10.1001/jamaophthalmol.2014.3459.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaophthalmol.2014.3459</ArticleId><ArticleId IdType="pubmed">25275721</ArticleId></ArticleIdList></Reference><Reference><Citation>Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF, American Academy of Ophthalmology Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision) Ophthalmology. 2016;123:1386&#x2013;1394. doi: 10.1016/j.ophtha.2016.01.058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ophtha.2016.01.058</ArticleId><ArticleId IdType="pubmed">26992838</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein M, Bell MJ, Ang LC. Hydroxychloroquine neuromyotoxicity. J Rheumatol. 2001;27:927&#x2013;2931.</Citation><ArticleIdList><ArticleId IdType="pubmed">11128688</ArticleId></ArticleIdList></Reference><Reference><Citation>Costedoat-Chalumeau N, Hulot JS, Amoura Z, Leroux G, Lechat P, Funck-Brentano C, Piette JC. Heart conduction disorders related to antimalarials toxicity: an analysis of electrocardiograms in 85 patients treated with hydroxychloroquine for connective tissue diseases. Rheumatology (Oxford) 2007;46:808&#x2013;810. doi: 10.1093/rheumatology/kel402.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kel402</ArticleId><ArticleId IdType="pubmed">17202178</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanouriakis A, Kostopoulou M, Cheema K, Anders HJ, Aringer M, Bajema I, Boletis J, Frangou E, Houssiau FA, Hollis J, Karras A, Marchiori F, Marks SD, Moroni G, Mosca M, Parodis I, Praga M, Schneider M, Smolen JS, Tesar V, Trachana M, van Vollenhoven RF, Voskuyl AE, Teng YKO, van Leew B, Bertsias G, Jayne D, Boumpas DT. 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020;79:713&#x2013;723. doi: 10.1136/annrheumdis-2020-216924.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-216924</ArticleId><ArticleId IdType="pubmed">32220834</ArticleId></ArticleIdList></Reference><Reference><Citation>Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100:S1&#x2013;S276. doi: 10.1016/j.kint.2021.05.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2021.05.021</ArticleId><ArticleId IdType="pubmed">34556256</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>